Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. 3 independent directors (4 non-independent directors). Scientific Director & Executive Director Germano Tarantino was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Apr 30
Pharmanutra S.p.A. announces Annual dividend, payable on May 06, 2026 Pharmanutra S.p.A. announced Annual dividend of EUR 1.2000 per share payable on May 06, 2026, ex-date on May 04, 2026 and record date on May 05, 2026. 공시 • Mar 19
Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026 Pharmanutra S.p.A., Annual General Meeting, Apr 27, 2026, at 15:00 W. Europe Standard Time. 공시 • Mar 18
Pharmanutra S.p.A. announces Annual dividend, payable on May 07, 2025 Pharmanutra S.p.A. announced Annual dividend of EUR 1.0000 per share payable on May 07, 2025, ex-date on May 05, 2025 and record date on May 06, 2025. 공시 • Mar 06
Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025 Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2025, at 11:00 W. Europe Standard Time. Reported Earnings • Nov 15
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €28.0m (up 28% from 3Q 2023). Net income: €4.27m (up 71% from 3Q 2023). Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe. Buy Or Sell Opportunity • Nov 07
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to €53.40. The fair value is estimated to be €43.63, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 29% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Reported Earnings • Sep 11
Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023) Second quarter 2024 results: EPS: €0.67 (up from €0.19 in 2Q 2023). Revenue: €33.2m (up 27% from 2Q 2023). Net income: €6.27m (up 248% from 2Q 2023). Profit margin: 19% (up from 6.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 4% per year. Buy Or Sell Opportunity • Aug 22
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 2.1% to €50.90. The fair value is estimated to be €42.30, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has declined by 3.2%. Revenue is forecast to grow by 32% in 2 years. Earnings are forecast to grow by 99% in the next 2 years. Reported Earnings • May 17
First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023) First quarter 2024 results: EPS: €0.27 (down from €0.56 in 1Q 2023). Revenue: €24.0m (up 1.3% from 1Q 2023). Net income: €2.63m (down 52% from 1Q 2023). Profit margin: 11% (down from 23% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 29
Upcoming dividend of €0.85 per share Eligible shareholders must have bought the stock before 06 May 2024. Payment date: 08 May 2024. Payout ratio is a comfortable 64% but the company is not cash flow positive. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.1%). Reported Earnings • Mar 17
Full year 2023 earnings released: EPS: €1.33 (vs €1.56 in FY 2022) Full year 2023 results: EPS: €1.33 (down from €1.56 in FY 2022). Revenue: €102.0m (up 23% from FY 2022). Net income: €12.8m (down 15% from FY 2022). Profit margin: 13% (down from 18% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. 공시 • Jan 14
Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024 Pharmanutra S.p.A., Annual General Meeting, Apr 16, 2024. Agenda: To approval of the Financial Statements as of 31?? December 2023. 공시 • Jan 13
Pharmanutra S.p.A. to Report Q2, 2024 Results on Sep 09, 2024 Pharmanutra S.p.A. announced that they will report Q2, 2024 results on Sep 09, 2024 Reported Earnings • Nov 09
Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022) Third quarter 2023 results: EPS: €0.26 (down from €0.48 in 3Q 2022). Revenue: €22.3m (up 8.2% from 3Q 2022). Net income: €2.50m (down 46% from 3Q 2022). Profit margin: 11% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe. Reported Earnings • Sep 13
Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022) Second quarter 2023 results: EPS: €0.19 (down from €0.49 in 2Q 2022). Revenue: €25.9m (up 24% from 2Q 2022). Net income: €1.80m (down 62% from 2Q 2022). Profit margin: 7.0% (down from 23% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.1% growth forecast for the Personal Products industry in Europe. Board Change • Jul 26
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. President of Supervisory Board Michele Giordano was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.